Equipped with a team of seasoned scientists with facilities specifically to meet very challenging requirements in the development of targeted immunotherapy for pancreatic cancer, Creative Biolabs offers fast and reliable support for any phase of engineering pancreatic cancer cell PANC-1 for self-destruction purposes.

Background of Pancreatic Cancer

Pancreatic cancer is one of the most lethal human cancers and the fourth-leading cause of cancer-related death in the United States. The incidence of pancreatic cancer is rising, and some reports predict that the number of new patients and pancreatic cancer deaths will double in the next ten years. Pancreatic cancer is very difficult to detect or diagnose at the early stages of the disease. Moreover, currently, there are limited effective treatments for patients with advanced diseases. In comparison to other cancer types, this cancer is significantly more resistant to chemotherapy, leaving patients with fewer options. New therapies such as targeted immunotherapies for pancreatic cancer are much needed.

Features of Human Pancreatic Cancer Cell Line PANC-1

PANC-1 was obtained from a primary tumor in the pancreatic duct of an epithelioid carcinoma patient. Metastases in one peripancreatic lymph node were discovered during a pancreaticoduodenectomy. In culture, the cell line was not found to secrete significant carcinoembryonic antigens. PANC-1 also shows epithelial cell like morphology and is poorly differentiated. Tumorigenicity describes a cancer cell line's ability or propensity to produce tumors in vivo. To estimate tumorigenicity, tumor volume, tumor mass, frequency to develop, and rate of growth have been used. Studies have shown that PANC-1 cells have high latency periods before tumor development after subcutaneous injection. Therefore, PANC-1 is often used as a useful in vitro model of non-endocrine pancreatic cancer for tumorigenicity studies.

Fig.1 Heat-map color-coding of one-dimensional plot of mean differences calculated for bucket intensities for hydrophilic extracts of Panc-1 and AsPC-1. (Watanabe, et al., 2012)

Pancreatic Cancer Cell PANC-1 Engineering Service at Creative Biolabs

With an experienced team of in-house experts in inspiring the lymphangiogenic potentiation of immunotherapy to Turning Cancer Cells Against Themselves, the pancreatic cell lines PANC-1 could be engineered into Cytokine Overexpression cells for cancer cell self-destruction purposes. Creative Biolabs has developed consultative Strategies to provide our clients with highly customizable solutions. Our seasoned scientists will work with you to develop a complete solution for your special needs.

Other strategies for engineering cancer cells for self-destruction, include but are not limited to:

• Engineering Cancer Cells with Target-specific Aptamer for Cancer Immunotherapy
• Engineering Cancer Cells with Aptamer-siRNA for Enhanced Antitumor T Cell Immunity
• Engineering Cancer Cells with Synthetic Immunomodulatory Gene Circuits for Cancer Immunotherapy
• Engineering Cancer Cells with Targeted siRNA for Cancer Immunotherapy

What's more, we are proficient at performing Self-destruction Assays, including but not limited to:

• Lymphangiogenesis Analysis
• Kinetics Analysis of Overexpressed Cytokine Secretion
• Naïve T Cell Infiltration Analysis
• Frequency Analysis of Antigen-presenting cells (APCs) Subsets in the Draining Lymph Nodes (dLNs)
• T Cell Activation Analysis
• Antigen-specific T Cell Response Analysis
• Determination of the Effect of Self-destruction Cancer Cells on Preexistent Tumor

For more detailed information, please feel free to contact us or directly send us an inquiry.

Reference

1. Watanabe, M.; et al. Metabolic profiling comparison of human pancreatic ductal epithelial cells and three pancreatic cancer cell lines using NMR based metabonomics. Journal of molecular biomarkers & diagnosis. 2012, 3(2).

For Research Use Only | Not For Clinical Use